Physician profile
Nathaniel Simmons
NPI 1487008181
$5,076.09
in general payments reported to CMS, 2019-2025
20 companies · $2,100 in 2025
The $2,100 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.17 · 2021: $373 · 2022: $586 · 2023: $564 · 2024: $1,436 · 2025: $2,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,099.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,505.15 | 2021-2025 | Argos, Hydrus Microstent, Ngenuity |
| Glaukos Corporation | $652.63 | 2022-2025 | Idosetr, Radius, Istent |
| Abbvie INC. | $442.07 | 2022-2025 | Alphagan P, Lumigan |
| Bausch & Lomb Americas INC. | $412.12 | 2023-2025 | Vyzulta, Xiidra, Miebo |
| Sight Sciences, INC. | $411.20 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Sun Pharmaceutical Industries INC. | $261.98 | 2022-2025 | Cequa, Xelpros |
| Tarsus Pharmaceuticals, INC. | $216.98 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $176.33 | 2021-2023 | |
| Dompe US, INC. | $156.11 | 2022-2025 | Oxervate |
| Oyster Point Pharma, INC. | $153.26 | 2022-2024 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $124.99 | 2024 | Syfovre |
| Amgen INC. | $114.51 | 2025 | Tepezza |
| Allergan, INC. | $97.86 | 2021-2022 | |
| Harrow Eye, LLC | $54.39 | 2024-2025 | Vevye, Iheezo |
| Aerie Pharmaceuticals, INC. | $45.54 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $38.09 | 2023-2024 | Tecnis Iol, Tecnis Simplicity |
| Carl Zeiss Meditec USA, INC. | $18.67 | 2024 | Iolmaster 700 |
| Astellas Pharma US INC | $17.47 | 2024 | Izervay |
| Horizon Therapeutics Plc | $15.19 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.